NUC-1031 in biliary tract cancer: from bench to bedside and back?

Volume: 85, Issue: 6, Pages: 1011 - 1014
Published: May 31, 2020
Abstract
In preclinical models of biliary tract cancer, NUC-1031 showed less potency than gemcitabine, no correlation with potential biomarkers and only moderate additive interaction in combination with cisplatin. These findings should prompt further careful pharmacological and translational studies to better define the purported therapeutic advantage of NUC-1031 over gemcitabine. That would be a more cautious approach than the phase III clinical trial...
Paper Details
Title
NUC-1031 in biliary tract cancer: from bench to bedside and back?
Published Date
May 31, 2020
Volume
85
Issue
6
Pages
1011 - 1014
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.